2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Sunday, October 21, 2018

4:30PM-6:00PM: Abstract Number: 936

Selective Deficiency of Serine Arginine-Rich Splicing Factor 1 (SRSF1) in T Lymphocytes Leads to mTORC1 Activation, Treg Dysfunction and Systemic Autoimmune Disease

3S109 ACR Abstract: SLE–Animal Models (934–939)

4:30PM-6:00PM: Abstract Number: 946

Short-Term Safety of Fractional-Dose Yellow Fever Vaccination in Autoimmune Rheumatic Diseases and Kinetics of White Blood Cells

3S104 ACR Abstract: Infection-Related Rheumatic Disease (946–951)

4:30PM-6:00PM: Abstract Number: 928

Single Cell RNA-Sequencing of Rheumatoid Synovial Fibroblasts Reveals a Disease-Associated Spatial Gradient Modulated By Inductive Notch Signaling

3S107 ACR Abstract: RA–Etiology & Pathogenesis I (928–933)

4:30PM-6:00PM: Abstract Number: 979

Stopping Medicines for Inactive Juvenile Idiopathic Arthritis: What Do Patients and Families Consider?

3S115 ACR/ARHP Abstract: Pediatric Rheum (976–981)

4:30PM-6:00PM: Abstract Number: 961

The Association of Biologic Drug-Levels with Infection Risk: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

3S108 ACR Abstract: RA–Treatments II: Safety (958–963)

4:30PM-6:00PM: Abstract Number: 959

The Prevalence of Methotrexate Associated Hepatotoxicity in a Multi-Hospital Health System

3S108 ACR Abstract: RA–Treatments II: Safety (958–963)

4:30PM-6:00PM: Abstract Number: 927

The Reprogramming of Regulatory T Cells to a Th17 Phenotype in Systemic Juvenile Idiopathic Arthritis

3S106 ACR Abstract: Pediatric Rheumatology–Basic Science (922–927)

4:30PM-6:00PM: Abstract Number: 960

The Risk of Gastrointestinal Perforations Associated with Biologic Disease-Modifying Anti-Rheumatic Drugs Used in Rheumatoid Arthritis: A Nationwide Swedish Cohort Study

3S108 ACR Abstract: RA–Treatments II: Safety (958–963)

4:30PM-6:00PM: Abstract Number: 958

Tocilizumab and the Risk for Cardiovascular Disease Events Among Rheumatoid Arthritis Patients: A Direct Comparison in Real World Setting

3S108 ACR Abstract: RA–Treatments II: Safety (958–963)

4:30PM-6:00PM: Abstract Number: 929

Transcriptional Profiling of the Subcutaneous Rheumatoid Nodule: An Insight into Pathogenic Mechanisms and Cellular Content

3S107 ACR Abstract: RA–Etiology & Pathogenesis I (928–933)

4:30PM-6:00PM: Abstract Number: 976

Transitioning from Paediatric to Adult Health Services: Development of an Integrated Programme Incorporating Patient and Provider Values

3S115 ACR/ARHP Abstract: Pediatric Rheum (976–981)

4:30PM-6:00PM: Abstract Number: 978

Treat-to-Target Study for Improved Outcome in Polyarticular Juvenile Idiopathic Arthritis

3S115 ACR/ARHP Abstract: Pediatric Rheum (976–981)

4:30PM-6:00PM: Abstract Number: 926

Truncating Mutations in SAMD9L Cause an Early-Onset Immune-Dysregulatory Syndrome of Neutrophilic Panniculitis, Interstitial Lung Disease and Cytopenias

3S106 ACR Abstract: Pediatric Rheumatology–Basic Science (922–927)

4:30PM-6:00PM: Abstract Number: 917

Type 1 Interferon Levels Correlates with Age of Diagnosis and Ethnicity in Systemic Lupus Erythematous

3S103 ACR Abstract: Genetics, Genomics & Proteomics: Precision Medicine (916–921)

4:30PM-6:00PM: Abstract Number: 950

Ultrasonographic Examinations Show Highly Prevalent Abnormalities of Hamstring Tendons in Lyme Arthritis Patients

3S104 ACR Abstract: Infection-Related Rheumatic Disease (946–951)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].